American Journal of Cardiology
Volume 103, Issue 2 , Pages 227-231 , 15 January 2009

Differential Use of Warfarin for Secondary Stroke Prevention in Patients With Various Types of Atrial Fibrillation

  • William R. Lewis, MD

      Affiliations

    • MetroHealth Campus, Case Western Reserve University, Cleveland, Ohio
    • Corresponding Author InformationCorresponding author: Tel: 216-778-2349; fax: 216-778-3927
    • ,
  • Gregg C. Fonarow, MD

      Affiliations

    • University of California, Los Angeles, Los Angeles, California
    • ,
  • Kenneth A. LaBresh, MD

      Affiliations

    • Masspro, Waltham, Massachusetts
    • ,
  • Christopher P. Cannon, MD

      Affiliations

    • Cardiovascular Division, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts
    • ,
  • Wenqin Pan, PhD

      Affiliations

    • Duke Clinical Research Institute, Durham, North Carolina
    • ,
  • Dennis M. Super, MD

      Affiliations

    • MetroHealth Campus, Case Western Reserve University, Cleveland, Ohio
    • ,
  • Suzanne A. Sorof, MD

      Affiliations

    • MetroHealth Campus, Case Western Reserve University, Cleveland, Ohio
    • ,
  • Lee H. Schwamm, MD

      Affiliations

    • Department of Neurology, Massachusetts General Hospital, Boston, Massachusetts

Received 11 May 2008 ,Revised 28 August 2008 ,Accepted 28 August 2008.

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.

 The data analysis of this study was performed by the Duke Clinical Research Institute, Durham, North Carolina, and funded by the American Heart Association, Dallas Texas. Dr. Super was supported by Grant No. M01 RR000080 from the National Center for Research Resources, National Institutes of Health, Bethesda, Maryland. Dr. Lewis has received speaker honoraria from Reliant Pharmaceuticals. Dr. Fonarow has received research grants from GlaxoSmithKline and honoraria from GlaxoSmithKline, Merck, Schering-Plough, and Bristol Myers Squibb and is or has been a consultant for Glaxo-Smith-Kline, Schering-Plough, Merck, and Bristol Myers Squibb. Dr. Cannon has received research grants from Accumetrics, AstraZeneca, Bristol-Myers Squibb, Glaxo Smith Kline, Merck, Sanofi-Aventis, and Schering Plough.

PII: S0002-9149(08)01581-6

doi: 10.1016/j.amjcard.2008.08.062

American Journal of Cardiology
Volume 103, Issue 2 , Pages 227-231 , 15 January 2009

Article Tools

* Image Usage & Resolution